Angiogenesis Inhibitors: all 4,430 studies that test it

Page 22 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.

• Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia PatientsCompletedNCT06146478Phase 3
• Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein OcclusionCompletedNCT06146309Not applicable
• First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive PatientsActive, not recruitingNCT06121401Phase 4
• Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular LymphomaActive, not recruitingNCT06112847Phase 2
• Safety & Efficacy of Thalidomide in Children With Transfusion Dependent ThalassemiaCompletedNCT06098014Phase 1
• A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisActive, not recruitingNCT06096779Phase 2
• Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06055816Phase 2
• MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaActive, not recruitingNCT06042725Phase 1
• A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TAREActive, not recruitingNCT06040099Phase 2
• A Study of Lorlatinib in Combination With Ramucirumab in People With Lung CancerActive, not recruitingNCT06007937Phase 1/2
• A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular CarcinomaWithdrawnNCT06006286Phase 1/2
• Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal CancerActive, not recruitingNCT05999812Phase 2
• A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical CancerWithdrawnNCT05998941Phase 2
• Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT05980000Phase 2
• Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal CancerActive, not recruitingNCT05969899Phase 2
• A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's LymphomaActive, not recruitingNCT05950165Phase 1/2
• SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary DiseaseCompletedNCT05900882Phase 2
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TWithdrawnNCT05886257Phase 2
• Parsaclisib in Patients With Relapsed or Refractory Follicular LymphomaWithdrawnNCT05867030Phase 1
• A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 InjectionCompletedNCT05865574Phase 1
• Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaActive, not recruitingNCT05821088Phase 2
• Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT05804032Phase 3
• Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male VolunteersCompletedNCT05800418Phase 1
• GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT05797948Not applicable
• Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)Active, not recruitingNCT05797246Phase 2
• RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal CancerStatus unknownNCT05785325Phase 2
• Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingNCT05775159Phase 2
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TStatus unknownNCT05760599Phase 2
• Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC PatientsActive, not recruitingNCT05751187Phase 2
• A Dosing Study of Intravitreal Bevacizumab for Retinopathy of PrematurityCompletedNCT05712642Phase 3
• Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of PrematurityCompletedNCT05701124Phase 3
• Elimination of Minimal Residual Disease After TransplantActive, not recruitingNCT05690984Phase 2
• A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular LymphomaActive, not recruitingNCT05683171Phase 1/2
• Safety and Efficacy of Faricimab in Patients With NPDRCompletedNCT05681884Phase 2
• Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung AdenocarcinomaStatus unknownNCT05675033Phase 2
• Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous CarcinomaStatus unknownNCT05665023Phase 2
• Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell LymphomaTerminatedNCT05660967Phase 2
• Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyActive, not recruitingNCT05633602Phase 3
• FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerActive, not recruitingNCT05627635Phase 1/2
• Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to AfliberceptStatus unknownNCT05610488Phase 4
• Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled TrialActive, not recruitingNCT05610319Phase 4
• Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular DegenerationCompletedNCT05604989Phase 3
• Immunomodulators on HIV-1 ReservoirStatus unknownNCT05598580Phase 4
• Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular DegenerationCompletedNCT05587062Phase 3
• CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal CancerActive, not recruitingNCT05585814Phase 2
• First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm TrialStatus unknownNCT05574998Phase 2
• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Phase 3
• Study of Teclistamab in Combination in Elderly Patients With Multiple MyelomaActive, not recruitingNCT05572229Phase 2
• A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)Active, not recruitingNCT05562947Phase 3
• A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After TreatmentActive, not recruitingNCT05556798Phase 1
• Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative StudyCompletedNCT05555329Phase 4
• Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal CancerStatus unknownNCT05551247Phase 2
• Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCCActive, not recruitingNCT05546879Phase 1
• Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung CancerStatus unknownNCT05529355Phase 2
• A Study of Thalidomide in the Treatment of Refractory Uremic PruritusStatus unknownNCT05525234Phase 4
• Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/AmplificationWithdrawnNCT05510427Phase 1
• Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and DexamethasoneStatus unknownNCT05509374Phase 2
• Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH TrialActive, not recruitingNCT05497804Phase 2
• Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 MutationActive, not recruitingNCT05491811Phase 2
• Lenalidomide in the Treatment of Refractory Cutaneous DermatomyositisStatus unknownNCT05488327Not applicable
• Evaluating Novel Therapies in ctDNA Positive GI CancersActive, not recruitingNCT05482516Phase 3
• A Phase I Clinical Trial of Bevacizumab InjectionCompletedNCT05476341Phase 1
• A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Phase 3
• Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLCStatus unknownNCT05448781Phase 2
• Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerActive, not recruitingNCT05445778Phase 3
• PVd Versus Vd in NDMM Patients With RIStatus unknownNCT05432414Phase 2
• Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)Active, not recruitingNCT05429268Phase 3
• RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSLStatus unknownNCT05425654Phase 2
• Golden Halo, Static Magnetic and Electric Field Device, in Recurrent GlioblastomaWithdrawnNCT05410301Not applicable
• Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMMWithdrawnNCT05408026Phase 1/2
• Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung CancerActive, not recruitingNCT05407155Not applicable
• Efficacy and Safety of T+A+RAD in HCCStatus unknownNCT05396937Phase 2
• Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical TrialStatus unknownNCT05392257Phase 2
• Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBCStatus unknownNCT05386524Phase 2
• Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain MetastasesStatus unknownNCT05357417Phase 2
• Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver TransplantationStatus unknownNCT05355155Phase 2
• A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)CompletedNCT05345236Phase 3
• GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaActive, not recruitingNCT05335018Phase 2
• A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural EffusionStatus unknownNCT05330065Phase 1/2
• A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian CancerStatus unknownNCT05325229Phase 2
• A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung CancerCompletedNCT05318443Phase 3
• TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal CancerStatus unknownNCT05314101Phase 2
• Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT05310344Phase 2
• Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic CancerStatus unknownNCT05298020Phase 2
• Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein OcclusionsStatus unknownNCT05290948Phase 2
• Ranibizumab Versus Aflibercept for CRVO in Young Patients.Status unknownNCT05282420Phase 4
• Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)Status unknownNCT05277675Not applicable
• Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung CancerStatus unknownNCT05273814Phase 1
• Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal CancerStatus unknownNCT05266820Phase 2
• A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHLTerminatedNCT05265975Phase 1/2
• Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R MutationCompletedNCT05263947Phase 2
• Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic CholangiocarcinomaStatus unknownNCT05251662Phase 2
• A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic RetinopathyStatus unknownNCT05248334Phase 1
• A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical CancerStatus unknownNCT05247619Phase 2
• A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)Active, not recruitingNCT05245968Phase 1
• Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1
• SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
• A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Phase 3
• A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular EdemaActive, not recruitingNCT05224102Phase 4
• The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting ConditionsStatus unknownNCT05218616Phase 1

← Angiogenesis Inhibitors overview